

**Basingstoke, Southampton and Winchester  
District Prescribing Committee (DPC)**

**Recommendations of the meeting of 11 June 2013**

**Supported or limited support, e.g. specialist recommendation/initiation**

- **Dapagliflozin- a new oral medication for the treatment of diabetes-** Local specialists are likely to suggest a niche use for this add-on therapy, rather than routine general use. This requires further confirmation at the August DPC meeting and/or following publication of NICE Guidance.
- **Wound Formulary Handbook, February 2013** - minor amendments were agreed around the use of metronidazole gels and Zetuvit E sterile dressings sizes.
- **New products for Actinic Keratosis (AK) - Ingenol gel (Picato®)** was supported for short-term use locally (2-3 days) as an option in the treatment of non-hyperkeratotic and non-hypertrophic AK. **5-aminolaevulinic acid (Ameluz®)** was supported for prescribing by specialists only (classified 'red'). In contrast, **Imiquimod cream 3.75% (Zyclara®)** was not supported, and a reminder that **Imiquimod cream 5% (Aldara®)** remains unsupported for local use in AK.
- **Fidaxomicin, new oral medication for use in Clostridium difficile infection** - The DPC supported this for third line niche use, on the advice of a specialist in microbiology in exceptional cases.
- **Teriparatide injection** - this was supported for niche (unlicensed) use in atypical fracture healing in small numbers of exceptional cases. The medication should be prescribed by a specialist for all indications (i.e. remains 'red')
- **Naltrexone-** A shared care guideline for alcohol misuse was approved in principle. There is however a need to clarify future funding of FP10 costs incurred now that the budget for alcohol misuse services sits with public health teams in the Local Authorities.
- **Low dose Methotrexate-** abridged shared care guidelines were approved with minor amendments. There remains a strong emphasis on the use of the 2.5mg tablets in preference to higher strengths, on safety grounds. 10mg tablets may be required only in exceptional cases.
- **Oxazepam-** added to UHS and Southampton City Joint Formulary for second line use in older patients with liver impairment undergoing alcohol detoxification therapy.

**Not Supported currently**

- **Linaclotide, new medication in IBS-** not supported currently due to the lack of good quality evidence of clinical benefit.
- **Ranolazine in CHD-** remains unsupported for routine use locally.

**Information / Reminders / Updates/ Safety Messages / NICE**

- **Osteoporosis Guidelines and Denosumab shared care guidelines** -Updates approved, including new safety advice on both strontium and denosumab. A reduction in strontium use will be likely as a result of this, especially in much older people. Two bisphosphonates, alendronate and then risedronate, should be tried before considering moving to other options such as denosumab. GPs may initiate denosumab without referral (if confident to do so) or on following telephone advice from a specialist. Re-referral remains an option of course, and denosumab remains officially 'amber' for the time being. Denosumab safety monitoring is currently being added to some local Near Patient Testing LES's that exist, to support shared care.

**Summarised on behalf of the District Prescribing Committee  
Julia Bowey (Southampton City CCG) 09.07.13**